Lb Pharmaceuticals (LBRX) Net Income towards Common Stockholders (2024 - 2026)

Lb Pharmaceuticals has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$19.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 259.1% year-over-year to -$19.1 million; the trailing twelve-month figure through Mar 2026 stood at -$14.2 million (changed N/A YoY), and the FY2025 full-year result was -$25205.0, up 60.06% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$19.1 million, down from $13.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $58.0 million in Q4 2024, with the low at -$19.1 million in Q1 2026.
• Average Net Income towards Common Stockholders over 3 years is $4.9 million, with a median of -$4.4 million recorded in 2025.
• Year-over-year, Net Income towards Common Stockholders soared 74.92% in 2025 and slumped 259.1% in 2026.
• Tracing LBRX's Net Income towards Common Stockholders over 3 years: stood at $58.0 million in 2024, then slumped by 76.35% to $13.7 million in 2025, then plunged by 239.0% to -$19.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$19.1 million (Q1 2026), $13.7 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.

Peer Comparison